

IDS
#37

ALLIA.143A



PATENT

RECEIVED

Applicant : Habib Zaghouani) Group Art Unit: 1644
App. No. : 08/779,767)
Filed : January 7, 1997)
For : COMPOUNDS,)
COMPOSITIONS AND)
METHODS FOR THE)
ENDOCYTIC)
PRESENTATION OF)
IMMUNOSUPPRESSIVE)
FACTORS)

OCT 03 2001

TECH CENTER 1600/2900

Examiner : P. Nolan

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c)(2) before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Sept. 20, 2001


By: Daniel Hart
Daniel Hart

10/03/2001 MBERHE 00000059 08779767

01 FC:126

180.00 OP

Registration No. 40,637
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550

 FORMPTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ALLIA.143A	APPLICATION NO. 08/779,767	RECEIVED OCT 03 2001 TECH CENTER 1600/2900
	APPLICANT Habib Zaghouni		
	FILING DATE January 7, 1997	GROUP 1644	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	US App. No. 09/623,728 US Natl. Phase of PCT App. No. PCT/US99/15225	07/06/99	Zaghouni, Habib			
	US App. No. 09/111,123	07/06/98	Zaghouni, Habib			
	US App. No. 09/873,901	06/04/01	Zaghouni, Habib			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/30706	07/16/98	PCT				

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		
	1.	Arnold et al., Multiple levels of peripheral tolerance, <i>Immunol. Today</i> , 14:12-14 (1993)
	2.	Fowlkes et al., T-cell tolerance, <i>Curr. Opin. Immunol.</i> , 5:873-879 (1993)
	3.	Jenkins et al., Molecules involved in T-cell costimulation, <i>Curr Opin. Immunol.</i> , 5:361-367 (1993)
	4.	Kosaka et al., Tolerance of CD8+ T Cells Developing in Parent F1 Chimeras Prepared with Supralethal Irradiation: Step-Wise Induction of Tolerance in the Intrathymic and Extrathymic Environments, <i>J. Exp. Med.</i> , 177:367-378 (1993)
	5.	McComack et al., Profound Deletion of Mature T Cells in Vivo by Chronic Exposure to Exogenous Superantigen, <i>J. Immunol.</i> , 150:3785-3792 (1993)
	6.	Rocha et al., Peripheral Selection of the T Cell Repertoire, <i>Science (Washington, D.C.)</i> , 251:1225-1228 (1991)
	7.	Webb et al., Extrathymic Tolerance of Mature T Cells: Clonal Elimination as a Consequence of Immunity, <i>Cell.</i> , 63:1249-1256 (1990)
	8.	Zaghouni et al., Cells Expressing an H Chain Ig Gene Carrying a Viral T Cell Epitope are Lysed by Specific Cytolytic T Cells, <i>J.Immunol.</i> , 148:3604-3609 (1992)
	9.	Zaghouni et al., Presentation of a Viral T Cell Epitope Expressed in the CDR3 Region of a Self Immunoglobulin Molecule, <i>Science</i> . 259:224-227 (1993)
	10.	Zaghouni et al., Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes, <i>Proc. Natl. Acad. Sci USA</i> . 88:5645-5649 (1991)
	11.	Zaghouni, Habib, 09/111,123, Filed July 6, 1998, Currently Pending Claims - Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors
	12.	Zaghouni, Habib, 09/341,011, Filed October 12, 1999, Currently Pending Claims - Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors
	13.	Zaghouni, Habib, 09/873,901, Filed June 4, 2001, Currently Pending Claims - Coupling of Peripheral Tolerance to Endogenous IL-10 Promotes Effective Modulation of T Cells and Ameliorates Autoimmune Disease

S:\DOCS\SGJ\SGJ-1264.DOC\091001

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	